Biocompatibility and Chemical Safety

Biocompatibility is a device conclusion—not a material property

Biocompatibility describes whether a medical device produces an appropriate biological response in its intended application. It depends on what contacts the body, which tissue is exposed, how much can be released, for how long, by which route and with what clinical consequence. The same material can be suitable in one device and unsuitable in another.

Biological evaluation is the structured process used to reach and maintain that conclusion. It brings together material knowledge, manufacturing information, chemical characterisation, toxicological assessment, biological testing, clinical experience and risk management. Testing can fill evidence gaps, but a list of passed tests is not the evaluation itself.

Begin with contact and exposure

The evaluation starts by mapping how the finished device contacts the patient or another person. Include both direct contact and indirect exposure through fluids, gases, medicinal products, pathways or transferred substances.

• Identify every patient-contacting and user-contacting component, surface and fluid or gas pathway.
• Define the anatomical location, tissue, circulating blood, breached surface or intact skin involved.
• Describe whether contact is direct, indirect, intermittent, repeated or produced by degradation.
• Determine exposure duration from the actual pattern of use, including repeated and cumulative contact where applicable.
• Consider maximum surface area, number of devices, dose, flow, volume and frequency of exposure.
• Identify vulnerable populations such as neonates, pregnant people or patients with impaired organ function when relevant.
• Include reasonably foreseeable misuse, damaged surfaces, incomplete cleaning and repeated reprocessing where they affect exposure.
• Map product variants and identify the configuration that represents the greatest biological challenge.

Use MTL-102 — Intended Purpose, Users and Use Environments to define the patient, user and clinical context. The contact model must remain consistent with product claims, instructions, risk analysis and validation.

Evaluate the finished device and its complete material system

The finished device is more than its base polymers, metals or ceramics. Biological exposure can be changed by additives, colourants, processing aids, lubricants, adhesives, coatings, inks, mould-release agents, cleaning residues, sterilisation products, packaging interactions and degradation during storage or use.

Material specifications should define what must remain controlled for safety. A trade name alone may not control formulation or supplier changes adequately. Record the actual grade, manufacturer, relevant composition, processing window and permitted alternatives.

See MTL-115 — Mechanical Design and Materials for material selection, ageing and manufacturing considerations that support the biological evaluation.

Plan a risk-based biological evaluation

The biological-evaluation plan should be established early enough to influence design and supplier decisions. It identifies existing evidence, biological hazards, relevant endpoints, uncertainties and the most appropriate ways to close gaps.

• Define the device, intended use, contact categories, exposure and configurations in scope.
• Identify applicable regulations, standards, product-specific requirements and regional expectations.
• Gather material composition, processing, supplier, sterilisation and previous-use information.
• Review literature, toxicological databases, clinical history, complaints and comparable-device evidence.
• Identify biological hazards and endpoint questions arising from the contact and material system.
• Assess whether chemical or biological equivalence to an existing device can be supported.
• State which questions can be answered by existing data, chemistry, toxicology, testing or clinical information.
• Define test articles, extraction conditions, laboratories, methods and acceptance rationale where testing is needed.
• Plan how deviations, unexpected compounds and inconclusive results will be assessed.
• Assign suitably qualified biological-safety and toxicology expertise and independent review where appropriate.

The plan should link directly to MTL-105 — Medical-device Risk Management. It is not enough to attach a test laboratory quotation to the development file; the manufacturer must explain why the proposed evidence is appropriate for the device and its risks.

Use chemical characterisation to understand exposure

Chemical characterisation develops knowledge of what the device contains and what it could release. ISO 10993-18 describes a stepwise framework covering materials of construction, composition, substances introduced during manufacture, extractables, leachables and degradation products.

Extraction conditions should be justified against the clinical exposure and the purpose of the study. Excessively aggressive conditions can generate compounds irrelevant to use; weak conditions can miss meaningful exposure. Record surface area, solvent, temperature, duration, preparation, pooling and analytical methods.

Chemical characterisation is not automatically a replacement for biological testing, nor is testing a substitute for chemistry. Each source of evidence answers different questions and should be integrated within the biological evaluation.

Translate chemical data into toxicological risk

A chemical list does not by itself establish safety. Toxicological risk assessment considers the identity and quantity of constituents, the patient exposure, exposure route and duration, relevant toxicological information, vulnerable populations and uncertainty.

• Confirm the analytical data and exposure estimate are suitable for the toxicological question.
• Identify compounds confidently and manage partially identified or unknown substances explicitly.
• Estimate the dose reaching the patient from the intended and worst credible use patterns.
• Select toxicological information relevant to the route, duration and biological endpoint.
• Establish tolerable exposure where scientifically justified and compare it with estimated exposure.
• Document uncertainty factors, data quality, read-across, mixtures and assumptions.
• Address substances of particular concern, genotoxicants and compounds without adequate data.
• Connect toxicological conclusions and remaining uncertainty to the product risk analysis.

ISO 10993-17 defines the process for toxicological risk assessment of medical-device constituents and works with chemical information generated under ISO 10993-18. Specialist toxicological judgement is needed; a margin calculated from unsuitable data can appear precise while giving a false conclusion.

Select biological endpoints from the risk questions

Biological endpoints are not a universal checklist. Their relevance depends on the device contact, exposure, materials, clinical use, existing data and identified hazards. The evaluation should address each applicable endpoint through an appropriate combination of evidence.

An endpoint can sometimes be addressed by composition, chemical characterisation, toxicological assessment, equivalence, published data or clinical history rather than a new animal test. The rationale must show that the evidence answers the biological-safety question for the finished device.

Test only when it closes a defined evidence gap

When testing is required, the test article and method must represent the biological challenge of the marketed device. Poor sample selection or preparation can make an otherwise valid method irrelevant.

• Select final, production-equivalent and appropriately sterilised test articles where required.
• Justify the worst-case material, colour, supplier, process, surface area, configuration and shelf-life condition.
• Account for devices with several materials, reusable devices, fluid paths, absorbable materials or nanomaterials.
• Use appropriate sample preparation, extraction ratios, vehicles, temperatures, durations and controls.
• Confirm laboratory competence, method suitability, quality controls and complete sample traceability.
• Predefine how validity criteria, deviations, unexpected responses and borderline results will be handled.
• Investigate failures rather than repeating tests until a passing result appears.
• Apply the principles of replacement, reduction and refinement and avoid unnecessary animal testing.
• Integrate results with chemistry, toxicology, risk controls and clinical evidence.

A test result belongs to the tested configuration. If the production device differs in material, processing, sterilisation, packaging or ageing, establish why the evidence remains applicable. Use MTL-106 — Verification and Validation for representative samples, protocols, acceptance criteria and controlled evidence.

Transfer biological-safety assumptions into production controls

The evaluation remains valid only while the characteristics on which it depends remain controlled. Design transfer must convert those assumptions into specifications, supplier controls, process limits and acceptance activities.

Incoming certificates do not replace supplier qualification or material identity controls where composition affects safety. Conversely, routine chemical testing of every batch may not be necessary when capable, validated processes and effective supplier controls protect the relevant characteristics.

Reassess changes and post-market information

Biological evaluation is a lifecycle activity. Changes that appear commercially or operationally minor can alter patient exposure and invalidate earlier evidence.

• Assess changes to supplier, grade, formulation, colour, additives, coatings and permitted regrind.
• Review new tooling, sites, process parameters, cleaning, joining and surface treatments.
• Evaluate packaging, sterilisation, shelf-life, transport and storage changes.
• Consider changes to contact, duration, frequency, patient population, indication or reprocessing.
• Monitor complaints, irritation, sensitisation, unexpected odour, residue, corrosion, degradation and adverse events.
• Review new toxicological information, regulatory restrictions and substance classifications.
• Use chemical and biological equivalence carefully; compare the complete finished devices and exposures.
• Update the biological-evaluation report and risk-management file when evidence or conclusions change.

A change does not automatically require repeating every test. It requires a documented assessment of what changed, what biological-safety questions are affected and which existing or new evidence resolves them.

Biological-safety work across the lifecycle

Build a connected biological-safety evidence chain

The biological-evaluation report should integrate the evidence and reach a reasoned conclusion for the finished device. It should not merely list test reports or state that materials are commonly used.

Maintain links from the biological-evaluation plan and report to requirements, the risk-management file, material specifications, supplier and process controls, verification records and change assessments. Use MTL-104 — Design Controls and Technical Documentation to organise that connected record.

Common misconceptions